STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit
Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersJewel Mullen was in kindergarten in 1961 when she almost died from measles. Now a physician, measles’ return frightens her.
By Chella·6h ago
Why it mattersHeidi Overton, Trump's pick for FDA head, will face questions at a Senate hearing. Follow along with our live blog.
By Chella·6h ago
Why it mattersPresident Trump and his aides boasted that every U.S. state wanted to participate in a drug pricing initiative through Medicaid.
President Trump and his aides boasted that every U.S. state wanted to participate in a drug pricing initiative through Medicaid. Several states said they weren'…
By Chella·6h ago
Why it mattersCongress is considering linking doctor payment rates to medical inflation under the proposed Patients First Act.
By Chella·6h ago